OQROGet OQRO Pro
Insider trade

McKesson Corporation (MCK)EVP & Chief HR Officer sold ~$180K

Leann B Smith, EVP & Chief HR Officer at McKesson Corporation, sold ~$180K of McKesson Corporation shares.

~$180K
Approx. value · 190 sh @ $945.00
2,989
Holds after · shares reported
Traded
Feb 17, 2026
Filed
Feb 19, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 18, 2024CongressDisclosed purchase of MCK — reported range $1,001 - $15,000
  2. Nov 1, 2025Federal contract · $1.4B obligatedDepartment of Veterans Affairs awarded McKesson Corporation: $1.41B obligated to date
  3. Dec 1, 2025Federal contract · $1.1B obligatedDepartment of Veterans Affairs awarded McKesson Corporation: $1.11B obligated to date
  4. Dec 2, 2025Congress · 1 personMembers of Congress: 2 purchases
  5. Dec 19, 2025CongressDisclosed sale of MCK — reported range $1,001 - $15,000
  6. Jan 1, 2026Federal contract · $1.1B obligatedDepartment of Veterans Affairs awarded McKesson Corporation: $1.09B obligated to date
  7. Jan 5, 2026InsiderOfficer sold ~$225K of MCK shares in the open market
  8. Jan 5, 2026Congress · 1 personMembers of Congress: 2 purchases
  9. Jan 16, 2026FDARecall: UDENYCA, pegfilgrastim-cbqv injection, 6 mg/0.6mL Single Dose Prefilled Syringe, Rx only, Manufactured by Accord BioPharma, Inc., 8041 Arco Corporate Drive, Su…
  10. Feb 1, 2026Federal contract · $1.1B obligatedDepartment of Veterans Affairs awarded McKesson Corporation: $1.06B obligated to date
  11. Feb 4, 2026Company filing · Form 8-K · ResultsReported its results
  12. Feb 4, 2026CongressDisclosed purchase of MCK — reported range $15,001 - $50,000
  13. Feb 6, 2026InsiderOfficer sold ~$313K of MCK shares in the open market
  14. Feb 10, 2026Layoff notice · 2700 North America Avenue West Seneca, NY, 14224Layoff notice filed in NY: 78 employees
  15. Feb 11, 2026InsiderOfficer sold ~$283K of MCK shares in the open market
  16. Feb 17, 2026 · this disclosureInsiderOfficer sold ~$180K of MCK shares in the open market

What came next

  1. Feb 19, 2026InsiderDirector sold ~$328K of MCK shares in the open market
  2. Mar 1, 2026Federal contract · $1.2B obligatedDepartment of Veterans Affairs awarded McKesson Corporation: $1.18B obligated to date
  3. Mar 2, 2026InsiderOfficer sold ~$2.7M of MCK shares in the open market
  4. Mar 3, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 3, 2026, Britt J. Vitalone, the company’s Executive Vice President and Chief Financial Officer, gave notice of his intention to retire from that role. Mr. Vitalone’s last day as our CFO will be May 28, 2026, and he will remain an employee through July 1, 2026.”
  5. Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  6. Apr 1, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
  7. Apr 1, 2026Federal contract · $1.2B obligatedDepartment of Veterans Affairs awarded McKesson Corporation: $1.19B obligated to date
  8. Apr 8, 2026CongressDisclosed partial sale of MCK — reported range $1,001 - $15,000
  9. Apr 28, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 1 more item)
  10. Apr 30, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  11. May 7, 2026Company filing · Form 8-K · ResultsReported its results
  12. May 26, 2026Insider · 2 peopleInsiders: 2 sales (~$4.5M)
  13. Jun 1, 2026Insider · 2 peopleInsiders: 2 sales (~$1.4M)
  14. Jun 2, 2026InsiderOfficer sold ~$514K of MCK shares in the open market
  15. Jun 5, 2026InsiderOfficer sold ~$102K of MCK shares in the open market
  16. Jun 9, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
  17. Jun 9, 2026InsiderCEO sold ~$3.76M of MCK shares in the open market
  18. Jun 10, 2026FDARecall: Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL), 26.3 mL Single-Dose Vial, For Intravenous Infusion ONLY, Rx only, Manufactured by: THYMOORGAN PHARMAZIE GmbH…
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for McKesson Corporation

For McKesson Corporation, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports, 47 fund holdings reports (13F) and 3 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MCK page.

Other recent filings by Leann B Smith, EVP & Chief HR Officer

The full history of Leann B Smith, EVP & Chief HR Officer is on the profile page.

How this filing works

Other disclosures at McKesson Corporation

Everything OQRO holds on this company is on its MCK page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data